stay tuned:
elixi news from the

European Commission Approves Janssen’s TREMFYA (guselkumab), a First-in-Class Treatment for Active Psoriatic Arthritis (PsA)

European Commission Approves Janssen’s TREMFYA (guselkumab), a First-in-Class Treatment for Active Psoriatic Arthritis (PsA)

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has approved TREMFYA®▼ (guselkumab) for the treatment of adult patients with active psoriatic arthritis (PsA) who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy. Guselkumab is the first approved fully human monoclonal antibody that selectively binds to the p19 subunit of interleukin (IL)-23 and inhibits its interaction with the IL23 receptor. It is already approved for the treatment of patients with moderate to severe plaque psoriasis. IL-23 is an important driver of the progression of inflammatory diseases including psoriasis and PsA, among others

PsA is a multifaceted, chronic, immune-mediated inflammatory disease that is progressive and is characterised by debilitating joint damage and inflammation, in addition to enthesitis, dactylitis, axial disease, and the skin lesions associated with psoriasis. The pain, stiffness and swelling of the joints and connective tissue can be severe and cause everyday tasks to become difficult. 2,3 In addition, more than half of people with PsA also live with another condition, such as cardiovascular disease, osteoporosis, inflammatory bowel disease or depression. 4,5 There is currently no known cure for PsA, and it is estimated that up to a third of the 14 million people living with psoriasis in Europe will go on to develop PsA.6,7 “Psoriatic arthritis is a progressive and debilitating disease and can have a huge impact not only on quality of life, but also on a person’s mental health. We welcome the news that guselkumab is now approved for the treatment of psoriatic arthritis,” said Jan Koren, President, European Federation of Psoriasis Patient Organisations (EUROPSO)*. “For patients, having more innovative treatment options available that improve the quality of life is good news, which we believe will bring hope to many patients in need of additional treatment options. We must now work to make this treatment accessible to patients across the European Union.”


Share this article

Pin it

SEE Also

we are specialized in the procurement and distribution of pharmaceutical products, medical devices all over the world

Stay Tuned

Subscribe to our newsletter


    Elixi International SA
    Vicolo Oldelli 12
    6830 Chiasso (TI)


    Tel.  +41 (0)91 6822040


    Elixi Europe Srl
    Via Uberti 6
    21100 Varese (VA)


    Tel.  +41 (0)91 6822040


    Elixi Pharma pte. ltd.
    6A  Shenton way #04-01
    Downtown gallery building


    Tel.  +41 (0)91 6822040

    ELIXI International SA

    Copyright 2023 ELIXI International SA.   |   All Rights Reserved   |   Privacy Policy   |   Cookie Policy